Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of VS-6063 in Malignant Pleural Mesothelioma
2013-001033-40Phase 2Terminated
- Sponsor
- Verastem Oncology
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of defactinib in pleural mesothelioma, sponsored by Verastem Oncology. Started Apr 2013; status: terminated.
02
Drugs
defactinib
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2013-001033-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001033-40.